A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Stopped The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.

Conditions

• Neoplasms Malignant

Interventions

• DRUG: dalotuzumab
• DRUG: MK-0752
• DRUG: ridaforolimus
• DRUG: MK-2206

Sponsor

Merck Sharp & Dohme LLC